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 Abstract 
  Background:   Chronic kidney disease (CKD) is associated with left-ventricular (LV) diastolic dys-
function (LVDD) which progresses to diastolic heart failure. However, biomarkers predicting 
LVDD in patients with CKD are largely unknown.   Methods:   In 93 patients with non-diabetic 
CKD, the relationships among echocardiography, high-sensitivity cardiac troponin T (hs-cTnT), 
B-type natriuretic peptide (BNP), and renal function were evaluated. LV mass index, peak early 
diastolic mitral filling velocity (E), peak early diastolic mitral annular velocity (E    ), and E/E     were 
recorded.   Results:   The E     values were significantly decreased and E/E    , BNP, and hs-cTnT in-
creased with increasing CKD stage. The CKD patients with LVDD with E      !  5 cm/s had a signifi-
cantly higher hs-cTnT level as well as a significantly higher BNP level compared to those with E    
  6 5 cm/s. The area under the receiver-operating characteristic curve for hs-cTnT and BNP to de-
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tect E     !  5 cm/s was 0.880 (p = 0.0101) and 0.741 (p = 0.0570), respectively. In multivariate analy-
sis, hs-cTnT and albuminuria were significantly associated with E    , and estimated glomerular 
filtration rate with the hs-cTnT level, after adjusting for age, cause of CKD, and other parameters. 
  Conclusions:   These data suggest that hs-cTnT may be a useful biomarker of LVDD in non-
diabetic CKD patients.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  The prevalence of heart failure with preserved ejection fraction (EF) has increased over 
time, while the rate of death from this disorder has remained unchanged  [1] . Individuals with 
heart failure with a normal EF are typically older and more likely to be female, and also have 
a higher likelihood of hypertension, obesity, renal failure, anemia, and atrial fibrillation   [1]  . 
In addition, chronic kidney disease (CKD) is associated with an increased mortality in pa-
tients with heart failure, and CKD-associated mortality is higher in patients with diastolic 
than systolic heart failure   [2]  . The European Working Group on heart failure with a normal 
EF proposed a new diagnostic algorithm in 2007   [3]  . The early diastolic velocity of the lon-
gitudinal motion of the mitral annulus (E    ) reflects the rate of myocardial relaxation. The 
velocity of the mitral annulus can be recorded by tissue Doppler imaging (TDI), and this has 
become an essential part of evaluating diastolic function by echocardiography. In patients 
with a variety of cardiac diseases, the TDI parameters, especially E    , were the most powerful 
predictors of cardiac death in the subsequent 2 years  [4] . Even in the absence of clinical heart 
failure, left ventricular (LV) diastolic dysfunction (LVDD) is associated with increased rates 
of future hospitalizations, development of heart failure, and all-cause mortality  [5] . Worsen-
ing stages of LVDD on echocardiography are associated with an incremental risk in adverse 
outcomes, including the development of clinical heart failure   [6]  . Accurately diagnosing 
LVDD could possibly lead to improved treatments and may have substantial health care im-
plications, from both clinical and resource utilization perspectives.
    Cardiac troponin T (cTnT) is the preferred biomarker for the diagnosis of acute myo-
cardial infarction. Elevated troponin levels can be detected in clinical settings in which 
myocardial injuries occur, as well as in several chronic disease states, including patients 
with coronary artery disease (CAD), heart failure, and CKD   [7–9]  . A highly sensitive (hs) 
assay for cTnT has recently been developed, which determines concentrations that are 
lower by a factor of 10 than those measurable with conventional assays. In patients with 
chronic heart failure   [10]   and chronic CAD   [11]  , circulating cTnT is detectable in almost all 
individuals with the highly sensitive assay, and higher levels correlate strongly with in-
creased cardiovascular mortality. In patients with renal failure, conventionally assessed 
cTnT levels may be elevated simply owing to delayed cTnT clearance, but numerous studies 
have shown the strong prognostic significance of elevated troponin levels in patients with 
CKD   [9, 12, 13]  .
    There have been several reports demonstrating that natriuretic peptides are a valuable 
tool that can be used to identify patients with severe diastolic dysfunction, however, they do 
not accurately predict mild or moderate diastolic dysfunction  [14–16] . An elevation of B-type 
natriuretic peptide (BNP) may be a hallmark of diastolic heart failure, independent of LV 
hypertrophy (LVH)   [17]  . In patients with heart failure with a normal EF, concentric hyper-
trophy or remodeling can be observed. In addition, several studies have demonstrated an 
independent association between troponin levels and the presence of LVH in hemodialysis 
  [18, 19]  , peritoneal dialysis   [20]  , and non-dialysis-dependent CKD patients   [12]  . To date, no 
data are available regarding the usefulness of serum hs-cTnT as a diagnostic marker of LVDD 168
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in patients with non-dialysis CKD. We hypothesized that the serum hs-cTnT may be associ-
ated with LVDD, and investigated the relationship between hs-cTnT values and LVDD in 
CKD patients without clinically apparent heart failure.
  Patients  and  Methods 
 Patients 
  Patients admitted to the Renal Unit of the Okayama University Hospital were included 
in this study. All patients were diagnosed as having CKD according to their estimated glo-
merular filtration rate (eGFR) and the presence of kidney injury as defined by National Kid-
ney Foundation K/DOQI Guidelines   [21, 22]  . Patients with cardiogenic shock, congestive 
heart failure, valvular heart disease, acute coronary syndrome, and other malignancies were 
excluded. Patients with diabetic nephropathy or nephrotic syndrome were also excluded. 
Hypertension was defined as systolic blood pressure (SBP)   6  140 mm Hg or diastolic blood 
pressure (DBP)   6  90 mm Hg, or the use of antihypertensive drugs. GFR was calculated ac-
cording to the simplified version of the MDRD (Modification of Diet in Renal Disease) for-
mula [eGFR = 194   !   (sCr) –1.094    !   (age) –0.287   (if female   !   0.739)]   [23]  . All procedures in the 
present study were carried out in accordance with the institutional and national ethical 
guidelines for human studies. The Ethical Committee of the Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences approved the study. Informed 
consent was obtained from each subject. This study was registered with the Clinical Trial 
Registry of the University Hospital Medical Information Network (registration No. 
UMIN000003614).
  Laboratory  Measurements 
  After fasting overnight, arterial blood pressure was measured by a physician in the 
morning after a 10-min rest period. The mean arterial pressure (MAP) was calculated as 
DBP + (SBP – DBP)/3. Serum and urine samples were obtained from patients in the morning 
after 12 h of fasting, and all parameters were measured immediately after blood sampling. 
In addition, aliquots were stored at –80    °    C until assayed for serum hs-cTnT. Cystatin C con-
centrations were measured with the sol particle homogeneous immunoassay method (Nes-
cauto GC Cystatin C    ; Alfresa Pharma, Osaka, Japan)   [24]  . Plasma BNP was measured by a 
rapid test system using a fluorescence enzyme immunoassay [E test Tosoh II (BNP); Tosoh 
Medics, Tokyo, Japan]. Serum hs-cTnT was determined by the Elecsys   /cobas  e TM   cTnT 4th-
generation assay (Roche Diagnostics) on the Elecsys 2010/cobas e411 and Modular     Analyt-
ics E170/cobas e601 immunoanalyzers (Roche Diagnostics) according to the instructions of 
the manufacturer   [11, 25]  . The lower limit of detection of the hs-cTnT assay was 3.00 pg/ml.
  E c h o c a r d i o g r a p h y  
  Echocardiography was performed using a cardiac ultrasound unit with a 2- to 3.5-MHz 
transducer. TDI was performed in all patients with images taken based on the guidelines of 
the American Society of Echocardiography   [26]  . LV end-diastolic/-systolic dimensions and 
end-diastolic/-systolic wall thickness of the interventricular septum and LV wall were deter-
mined using standard echocardiographic 2-D and M-mode measurements. Both EF and LV 
mass (LVM) were calculated from the M-mode echocardiogram. LVH was defined as the 
LVM index (LVMI)   1 125  g/m 2   in males and   1 110  g/m 2   in females. LVM was calculated ac-
cording to the formula of Devereux et al.   [27]  , using a correction factor of 0.8. Mitral inflow 
velocity was traced, and the following variables were derived: peak early (E) and late (A) 
transmitral flow velocities, and the ratio of early/late peak velocities (E/A).169
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    Tissue Doppler Imaging  
  A 6-mm sample volume at the septal corner of the mitral annulus was used for the api-
cal four-chamber view. Annular velocities were displayed in spectral pulsed-wave TDI. The 
early peak diastolic annular velocity (E    ) was determined from the TDI recordings and the 
mitral E/E     ratio was calculated. LV filling pressure was considered to be elevated when 
E/E     1 15 and normal when E/E    ! 8  [28] . Diastolic dysfunction was previously defined when 
E      !  8 cm/s   [29–31 ]  . In this study, patients with L VDD with E      !  5 cm/s were defined as 
having severe LVDD   [32]   because such patients had a worse prognosis than those with 
E      6  5 cm/s   [4, 33]  .
  Statistical  Analysis 
  Non-normally distributed variables were expressed as medians (interquartile ranges) 
and normally distributed variables as means   8   SD, as appropriate. p   !   0.05 was considered 
to be statistically significant. Variables showing a positively skewed distribution were natural 
logarithm transformed. Receiver-operating characteristic (ROC) curves were constructed to 
determine the optimal sensitivity and specificity, and the area under the curve (AUC) was 
calculated. Between-group comparisons were assessed for nominal variables with the    2  test. 
Differences among the groups were analyzed by one-way ANOVA followed by a post hoc   
  Tukey-Kramer test for multiple comparisons. Spearman’s rank correlation was used to de-
termine the correlations between two variables. A multivariate regression analysis was used 
to assess the predictors for E     and hs-cTnT. Statistical analysis was performed using the JMP 
software package release 8 (SAS Institute, Cary, N.C., USA).
  R e s u l t s  
 Patient  Characteristics 
  After the first evaluation, 93 CKD patients with a mean age of 54   8   14 years were in-
cluded in the study. The causes of CKD are listed in   table 1  . A total of 62 patients were on 
antihypertensive therapy (52 patients were being treated with angiotensin receptor blockers, 
10 with angiotensin-converting enzyme inhibitors, 37 with calcium channel antagonists, 
and 11 with other antihypertensive agents). Statins were administered to 19 patients and an-
tiplatelet therapy to 20 patients. Based on their eGFR levels, patients were classified into 
stages 1–5 ( table 1 ). Serum levels of biomarkers, including cystatin C, BNP, and hs-cTnT, were 
significantly elevated with increasing CKD stage. There were significant differences in the 
mean age, hemoglobin concentration, and LDL cholesterol among patients of different CKD 
stages. There were no significant differences in the MAP, daily albuminuria, serum albumin, 
HDL cholesterol, triglycerides, and HbA  1c   among the CKD groups. Echocardiographic and 
TDI assessments revealed significant differences in the LVMI, E/A, E    , and E/E     ( table 1 ). 
There were no significant differences in EF or left atrial diameter among the groups ( table 1 ). 
All patients demonstrated a normal LV systolic function.
    An Increase in Serum hs-cTnT and a Decrease in LV Filling Pressure Are Associated with 
CKD Stage 
  Patients in stages 1–5 CKD without diabetes had gradually decreased E     values (p   !  
0.0001;   table 1  ). In addition, gradual increases in serum hs-cTnT levels were observed with 
increasing CKD stage (p   !   0.0001;   table 1  ), with an average value of hs-cTnT in patients with 
eGFR  6 90 of 3.56; eGFR 60–89 of 4.52; eGFR 30–59 of 6.86; eGFR 15–29 of 11.10, and eGFR 
0–14 ml/min/1.73 m  2  of 20.41 pg/ml. The highest hs-cTnT concentration was found in pa-
tients in stage 5 CKD.170
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    Serum hs-cTnT Correlates with Cardiorenal Markers 
 In univariate analysis, serum ln hs-cTnT levels correlated negatively with E   (r = –0.5104, 
p   !   0.0001;   table 2  ), but were positively associated with daily albuminuria (r = 0.2574, p = 
0.0341), serum cystatin C (r = 0.7751, p   !   0.0001), MAP (r = 0.3460, p = 0.0018), and LVMI 
(r = 0.5195, p   !   0.0001;   table 2 ).
    Serum hs-cTnT and Plasma BNP Significantly Increase in CKD Patients with E      ! 5  cm/s 
  The non-diabetic CKD patients with severe LVDD detected by E      !  5 cm/s had signifi-
cantly higher serum hs-cTnT levels compared to those with E    6 5 cm/s ( fig. 1 a). The average 
value of hs-cTnT was 7.4   8   8.3 pg/ml in CKD patients with E      6  5 cm/s, whereas it was 17.0 
  8   7.3 pg/ml in those with E      !  5 cm/s. There were significant differences in plasma BNP, 
another biomarker of heart failure, between CKD patients with E      6  5 cm/s and those with 
E      ! 5  cm/s  ( fig. 1 b).
    The ability of using hs-cTnT to detect E      !  5 cm/s in patients with normal systolic func-
tion was assessed by ROC analysis (  fig. 2  ). The AUC for the ROC curve when hs-cTnT was 
used to detect E      !  5 cm/s was 0.880 (p = 0.0101), which denoted moderate accuracy. A hs-
Table 1.   Baseline characteristics of the study patients
CKD stage p
value
1 
(n = 11)
2 
(n = 30)
3 
(n = 23)
4 
(n = 15)
5 
(n = 14)
total 
(n = 93)
Age, years  .03387 .049814 .06189 .06489 .057812 . 54814 <0.0001
Gender, males/females  .003/8 .017/13 .012/11 .010/5 .008/6 0.50/43
Cause of CKD, n
Glomerulonephritis .010 .021 .016 .001 .003 .051
Nephrosclerosis .000 .007 .005 .011 .005 0.28
Other .001 .002 .002 .003 .006 .014
Current medication, n
ARBs/ACEIs .001 .010 0.18 .012 .011 0.52
CCBs .000 .008 .012 .008 .009 .037
MAP, mm Hg .086810 0.91811 0.93811 .093813 0.96810 0.92811 <0.1952
eGFR, ml/min/1.73 m2 .10289  .07289  .04589  .02384  .01183  .05283 <0.0001
Albuminuria, mg/day .123 (17–597) .297 (147–704) .123 (48–864) .418 (92–1,209) .620 (153–1,496) .289 (99–821) <0.1959
Cystatin C, mg/dl 00.880.1 01.080.2 01.480.3 02.580.4 03.780.7 01.881.1 <0.0001
Serum albumin, g/dl 04.280.3  03.980.6  03.980.4  03.880.4  03.980.5  03.980.5 <0.2827
Hemoglobin, g/dl 13.781.5 14.181.8 12.381.6 11.081.5 11.081.9 12.682.1 <0.0001
LDL cholesterol, mg/dl .104838  .129830  .113826  .104830  .104827  .114830 <0.0226
HDL cholesterol, mg/dl .060819  .056816  .052816  .050818  .047813  .053817 <0.2324
Triglycerides, mg/dl 0.77 (75–139) .129 (89–181) .109 (84–174) .132 (86–190) .122 (72–185) .119 (79–171) <0.6931
HbA1c, % 05.280.5 05.380.4 05.480.3  05.380.3  05.480.5  05.380.4 <0.3227
BNP, pg/ml .009 (7–16) .019 (5–33) .015 (8–32) .034 (21–68) .029 (9–53) 0.19 (9–42) <0.0473
hs-cTnT, pg/ml .003 .003 (3–4) .005 (3–9) .009 (7–16) 0.16 (8.5–27) .004 (3–9) <0.0001
EF, % 0.6886 .07086 .06886 .07089 .06886 0.6987 <0.8585
LVMI, g/m2 .071820 .090821  0.92820  .115836  .111843  .096830 <0.0019
LAD, mm 0.3487 .03485  .03485  .03886  .03586  0.3586 <0.1761
E/A 01.6 (1.1–2.3) 01.0 (0.9–1.5) 00.9 (0.8–1.1) 00.8 (0.7–1.0) 00.9 (0.7–1.0) 00.9 (0.8–1.2) <0.0001
E, cm/s 11.083.1  08.982.1  07.182.4  06.281.8  07.082.4  07.882.6 <0.0001
E/E 07.682.1  07.8821.9  09.682.7 10.282.7  08.882.6  08.982.6 <0.0160
N  on-normally distributed variables are expressed as medians (interquartile ranges) and normally distributed variables as means 8 SD. 
ACEI = Angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CCB = calcium channel blocker; LAD = left atrial 
diameter.171
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cTnT value of 9 pg/ml had a sensitivity of 100%, and a specificity of 76% (  fig. 2  a). The AUC 
for the ROC curve when BNP was used to detect E      !  5 cm/s was 0.741 (p = 0.0570), which 
also denoted a moderate degree of accuracy. A BNP value of 20.3 pg/ml had a sensitivity of 
90%, and a specificity of 57% (  fig. 2  b). The AUC for hs-cTnT was therefore greater than that 
for BNP.
    Multiple Regression Analysis for E     and hs-cTnT 
    Table 3   presents separate multiple regression models for E     and hs-cTnT. After adjust-
ment for age and the cause of CKD, the variable expected to influence E     was hs-cTnT in 
the biomarker-based model, and albuminuria in the CKD-based model (  table  3  a). 
Moreover, the factor expected to influence hs-cTnT was eGFR in the CKD-based model 
( table 3 b).
r value p value
Age –0.4765 <0.0001
MAP –0.3460 <0.0018
eGFR –0.6867 <0.0001
Albuminuria –0.2574 <0.0341
Cystatin C –0.7751 <0.0001
Serum albumin –0.1253 <0.2496
Hemoglobin –0.4221 <0.0001
LDL cholesterol –0.1754 <0.1246
HDL cholesterol –0.4361 <0.0001
Triglycerides –0.1254 <0.2739
HbA1c –0.2593 <0.0228
BNP –0.2178 <0.0661
EF –0.0301 <0.7964
LVMI –0.5195 <0.0001
LAD –0.3322 <0.0034
E/A –0.4311 <0.0001
E –0.5104 <0.0001
E/E –0.3363 <0.0032
L  AD = Left atrial diameter.
  Fig. 1.   The distribution of hs-
cTnT (  a  ) and BNP (  b  ) in CKD 
patients with or without severe 
LVDD.  a  n = 66 in the E    6 5 cm/s 
group and n = 10 in the E      ! 5 
cm/s group.   b  n = 68 in the E    6 5 
cm/s group and n = 10 in the E    
  ! 5 cm/s group. Severe LVDD was 
defined as E      !  5 cm/s by TDI. 
Table 2.   Univariate relationships 
of clinical and echocardiographic 
indices to ln hs-cTnT172
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  Discussion 
  In our study, we investigated the relationship between serum hs-cTnT and LVDD in pa-
tients with CKD and demonstrated that CKD patients with E      !  5 cm/s had significantly 
higher serum hs-cTnT levels compared to those with E      6  5 cm/s. The AUC for the ROC 
curve using hs-cTnT to detect E     !  5 cm/s was 0.880, which denoted moderate accuracy. Our 
data suggest that, in addition to plasma BNP, the recently established serum hs-cTnT value 
may therefore be associated with LVDD in CKD patients. In multivariate analysis, hs-cTnT 
and albuminuria were significant predictors of E     in the biomarker-based model and the 
  Fig. 2.   ROC curve comparing sensitivity and specificity of hs-cTnT (  a  ) and BNP (  b  ) for detecting LVDD 
with E      !  5 cm/s by echocardiography. The AUC for the ROC curve where hs-cTnT was used to detect 
E      !  5 cm/s was 0.880 (p = 0.0101). A hs-cTnT value of 9 pg/ml had a sensitivity of 100%, and a specificity 
of 76%. The AUC for the ROC curve where BNP was used to detect E      !  5 cm/s was 0.741 (p = 0.0570). A 
BNP value of 20.3 pg/ml had a sensitivity of 90%, and a specificity of 57%. 
 p
a    E(adjusted for age and cause of CKD)
Echocardiography-based model
MAP –0.040599 0.0452
EF –0.022496 0.4741
LVMI –0.010729 0.1900
Biomarker-based model
hs-cTnT –0.058090 0.0332
BNP –0.001469 0.8214
CKD-based model
eGFR –0.007911 0.3771
Albuminuria –0.000723 0.0154
b    hs-cTnT (adjusted for age and cause of CKD)
Echocardiography-based model
MAP –0.142268 <0.1511
EF –0.147041 <0.3180
E –0.888941 <0.0845
CKD-based model
eGFR –0.160545 <0.0001
Albuminuria –0.000015 <0.9907
Table 3.   Multivariate regression 
analysis of predictors of E( a ) 
and hs-cTnT (  b )173
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CKD-based model, respectively, and eGFR was significantly associated with hs-cTnT after 
adjusting for age and the etiology of kidney disease in non-diabetic CKD patients. 
    The cTnT concentration measured with a hs-cTnT assay is a prognostic factor for the 
incidence of cardiovascular death and heart failure in patients with stable chronic heart fail-
ure   [10]  , with stable CAD   [11]  , in the general population with a younger age   [34]  , and in se-
nior adults   [8]  . Our study demonstrated that CKD patients with LVDD indicated by an E    
value   !  5 cm/s had significantly higher hs-cTnT levels compared to those with E      6 5  cm/s. 
The median value of serum hs-cTnT was 17.0 pg/ml in CKD patients with LVDD with E     ! 5 
cm/s, and this value corresponded to quartile 4, which has been reported to have the highest 
cumulative incidence of cardiovascular death   [11]  . In our study, the difference in the ln hs-
cTnT between patients with E      !  5 and E      6  5 cm/s was 1.08 units. The adjusted hazard ratio 
per unit increase in the natural logarithm of hs-cTnT of the cumulative incidence of cardio-
vascular death and heart failure was 2.09 and 2.20, respectively   [11]  . Thus, the hs-cTnT level 
in patients with LVDD indicated by E     !  5 cm/s in this study was substantially higher, which 
may be sufficient to cause cardiovascular events in CKD patients. Our findings provide valu-
able insight into the relationship between hs-cTnT and LVDD with E      !  5 cm/s. We reported 
the performance of hs-cTnT for the detection of LVDD with E      !  5 cm/s in patients to have a 
moderate degree of accuracy (AUC = 0.880). However, the AUC for hs-cTnT was greater than 
that for BNP.
    Persistently elevated cardiac troponin is frequently observed among patients with end-
stage renal disease   [9, 35]  . The prevalence of increased troponin values among patients with 
chronic renal failure in the absence of clinically suspected ischemia, such as in our study, 
may be the result of small areas of clinically silent myocardial necrosis. However, other 
causes, such as increased LVM and impaired renal troponin excretion, have also been pro-
posed   [36]  . cTnT has a molecular weight of 37 kDa and that of cTnI (cardiac troponin I) is 
22.5 kDa. cTnI is released from the cell in complexes of TnT-I-C (77 kDa) and TnI-C (40 
kDa), while cTnT is released as free TnT or TnT-I-C complexes   [35]  . Recent studies have 
shown that both cTnT and cTnI are degraded in myocardial cells, and then released as small 
molecules that are still detected by the assays  [37, 38] . Diris et al.  [37]  demonstrated that cTnT 
is split into fragments that range in size from 8 to 25 kDa, even in samples with measured 
cTnT concentrations that are   !  10 pg/ml. These fragments are small enough to be cleared by 
the kidneys, and therefore could be elevated in patients with renal failure owing to delayed 
clearance. In contrast, Fahie-Wilson et al.   [39]   and Bates et al.   [40]   reported that the form of 
cTnT observed in the serum of patients with kidney failure is predominantly the free intact 
form, and there is no evidence of cTnT fragments existing in the circulation. Their data are 
consistent with the view that circulating cTnT in renal failure patients reflects cardiac injury.
  CKD is an increasing public health problem  [41] . Cardiovascular disease is frequently as-
sociated with CKD, which is important, since individuals with CKD are more likely to die of 
cardiovascular disease than to develop kidney failure. Indeed, the term cardiorenal syndrome 
has been increasingly used, and a new classification was proposed because a large proportion 
of patients admitted to the hospital have various degrees of heart and kidney dysfunction  [42] . 
In our cohort, 48 patients (57%) had E      !  8 cm/s and 10 patients (12%) had E      !  5 cm/s. E     was 
significantly decreased with increasing CKD stage, and eGFR showed a significant associa-
tion with E      !  5 cm/s. LVDD is very common among CKD patients and may be associated 
with the subsequent development of heart failure and mortality   [43]  . In patients with heart 
failure, the presence of CKD is associated with a worse diastolic function, intracardiac con-
duction and prognosis   [2, 33]  . An impairment in the diastolic function in patients with CKD 
may occur very early, even in the absence of LVH   [44]  . In hypertensive patients in stage 2–5 
CKD, who are free of cardiovascular disease, E     evaluated by TDI was lower with lessening 
renal function, with very low values in stage 5 CKD, although all patients were free from heart 174
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failure   [44] .  E    has been demonstrated to be inversely related to the degree of fibrosis in isch-
emic, as well as normal, myocardial segments  [45] . Although the pathogenesis of LVH in CKD 
patients is considered to be multifactorial, hypertension, alterations in fluid and electrolyte 
balance, and anemia are identified as the major determinants of LV growth in CKD patients. 
However, beyond hemodynamic factors, other factors, e.g. inappropriate activation of the 
renin-angiotensin-aldosterone system, oxidative stress, inflammation and hyperactivation of 
collagen and muscle cell growth factors, may also play a role in LV growth in CKD.
  In this study, albuminuria was the most significant predictor of E   in non-diabetic CKD 
patients. An association of albuminuria with systolic and diastolic LV dysfunction in dia-
betic cardiomyopathy in type 2 diabetic patients was previously reported   [46]  . The mecha-
nism underlying the relationship between LVDD and albuminuria is unclear. In the present 
study, SBP and pulse pressure were both significantly higher in patients with E    ! 5 cm/s than 
in those with E      6  5 cm/s (p   !   0.001). Since systemic hypertension could cause glomerular 
hypertension and hyperfiltration, which leads to albuminuria, it may represent a candidate 
mechanism responsible for the relationship between LVDD and albuminuria. LVDD may 
cause volume overload of circulating plasma, thus leading to an increase in renal blood flow. 
Diastolic dysfunction might be associated with albuminuria via endothelial dysfunction. An 
impairment in tubular reabsorption of albumin may be one of the causes of albuminuria  [47] . 
Several molecules, including heart-type fatty acid binding proteins, can be synthesized by 
both cardiomyocytes and distal tubular epithelial cells in the kidneys, so that simultaneous 
dysfunction of the heart and kidney might occur in CKD patients.
  Study  Limitations 
 Several limitations of this study should be noted. First, our sample size is relatively small, 
and a larger cohort of CKD patients will need to be examined to confirm our findings. Sec-
ond, given that these results are cross-sectional, we may not draw definitive inferences on 
their direction or causality. Third, because of the multifactorial causes of diastolic dysfunc-
tion, it is possible that we did not fully control for all confounding variables, such as factors 
for mineral metabolism and vascular parameters.
  Conclusion 
  Among patients with non-diabetic CKD without LV systolic dysfunction who are at in-
creased risk for cardiovascular events, the serum hs-cTnT may be a significant biomarker for 
LVDD. Further investigation, including an outcome study elucidating the significance of hs-
cTnT as a prognostic factor, should be performed in a prospective study in the near future.
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